CN115989032A - 用于吸入施用的组合疗法 - Google Patents

用于吸入施用的组合疗法 Download PDF

Info

Publication number
CN115989032A
CN115989032A CN202180051794.2A CN202180051794A CN115989032A CN 115989032 A CN115989032 A CN 115989032A CN 202180051794 A CN202180051794 A CN 202180051794A CN 115989032 A CN115989032 A CN 115989032A
Authority
CN
China
Prior art keywords
solution composition
pharmaceutical solution
composition according
long
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180051794.2A
Other languages
English (en)
Chinese (zh)
Inventor
A·涅托奥雷利亚纳
M·梅索普鲁图拉诺
L·安德拉德贝尼特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Research SL
Original Assignee
Chemo Research SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72039503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN115989032(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemo Research SL filed Critical Chemo Research SL
Publication of CN115989032A publication Critical patent/CN115989032A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180051794.2A 2020-07-31 2021-07-30 用于吸入施用的组合疗法 Pending CN115989032A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382710.0 2020-07-31
EP20382710 2020-07-31
PCT/EP2021/071369 WO2022023515A1 (en) 2020-07-31 2021-07-30 Combination therapy for inhalation administration

Publications (1)

Publication Number Publication Date
CN115989032A true CN115989032A (zh) 2023-04-18

Family

ID=72039503

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180051794.2A Pending CN115989032A (zh) 2020-07-31 2021-07-30 用于吸入施用的组合疗法

Country Status (13)

Country Link
US (1) US20230270754A1 (https=)
EP (1) EP4188327B1 (https=)
JP (1) JP7828949B2 (https=)
KR (1) KR20230052903A (https=)
CN (1) CN115989032A (https=)
AU (1) AU2021314977B2 (https=)
BR (1) BR112023001689A2 (https=)
CA (1) CA3186956A1 (https=)
ES (1) ES3037198T3 (https=)
FI (1) FI4188327T3 (https=)
MX (1) MX2023001201A (https=)
PL (1) PL4188327T3 (https=)
WO (1) WO2022023515A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121714579A (zh) * 2026-02-25 2026-03-24 上海臣邦医药科技股份有限公司 一种三联复方吸入制剂的药物组合物及其制备方法和应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230270754A1 (en) 2020-07-31 2023-08-31 Chemo Research, S.L. Combination therapy for inhalation administration
WO2026057872A1 (en) * 2024-09-16 2026-03-19 Invox Belgium Nv Inhalable compositions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023065A2 (de) * 1998-10-17 2000-04-27 Boehringer Ingelheim Pharma Kg Lagerfähiges wirkstoffkonzentrat mit formoterol
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
CN105848641A (zh) * 2013-12-30 2016-08-10 奇斯药制品公司 格隆溴铵和福莫特罗组合的稳定的加压气雾剂溶液组合物
WO2017089404A1 (en) * 2015-11-25 2017-06-01 Jagotec Ag Pharmaceutical composition
CN109562061A (zh) * 2016-08-17 2019-04-02 奇斯药制品公司 用于copd的组合疗法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851317A (en) 1987-11-04 1989-07-25 E. I. Du Pont De Nemours And Company Laminar flow toning station having conductive and nonconductive elements therein
UA62917C2 (en) * 1995-06-27 2004-01-15 Berinher Inhelheim Kg Medicinal composition for generating propellant-free aerosols
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE19653969A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
AU2000250701B2 (en) 2000-05-22 2004-07-01 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
CA2436540C (en) 2000-10-31 2008-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and corticosteroids
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
JP2008538758A (ja) 2005-04-23 2008-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬に加えてベータ受容体刺激薬及びステロイドを含有する吸入用の医薬組成物
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
US20070293460A1 (en) 2005-10-31 2007-12-20 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
US20070098644A1 (en) 2005-10-31 2007-05-03 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
DE102006023756A1 (de) 2006-05-20 2007-11-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ethanolhaltige Aerosolformulierung für die Inhalation
UY30542A1 (es) 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
EP2515855B3 (en) 2009-12-23 2023-05-03 Chiesi Farmaceutici S.p.A. Combination therapy for COPD
SG181870A1 (en) 2009-12-23 2012-07-30 Chiesi Farma Spa Aerosol formulation for copd
BR112012015334A2 (pt) 2009-12-23 2016-03-15 Chiesi Farma Spa terapia combinada para doença pulmonar obstrutiva crônica
US20120220557A1 (en) 2011-02-17 2012-08-30 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
BR112015010842B1 (pt) 2012-12-21 2021-03-30 Boehringer Ingelheim Vetmedica Gmbh Uso da ciclesonida para o tratamento de doença das vias respiratórias em cavalos
GEAP201814192A (en) 2013-12-30 2018-02-26 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
ES2759247T3 (es) 2014-06-18 2020-05-08 Boehringer Ingelheim Vetmedica Gmbh Antagonistas muscarínicos y combinaciones de estos para el tratamiento de enfermedades de las vías respiratorias en caballos
WO2020167893A1 (en) 2019-02-13 2020-08-20 Molecular Infusions, Llc Methods for non-irritating pulmonary administration of cannabinoids using soft mist inhalers
US20230270754A1 (en) 2020-07-31 2023-08-31 Chemo Research, S.L. Combination therapy for inhalation administration

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023065A2 (de) * 1998-10-17 2000-04-27 Boehringer Ingelheim Pharma Kg Lagerfähiges wirkstoffkonzentrat mit formoterol
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
CN105848641A (zh) * 2013-12-30 2016-08-10 奇斯药制品公司 格隆溴铵和福莫特罗组合的稳定的加压气雾剂溶液组合物
WO2017089404A1 (en) * 2015-11-25 2017-06-01 Jagotec Ag Pharmaceutical composition
CN109562061A (zh) * 2016-08-17 2019-04-02 奇斯药制品公司 用于copd的组合疗法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
万忆春主编: "《实用儿科疾病诊疗精要》", vol. 1, 31 May 2019, 吉林科学技术出版社, pages: 134 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121714579A (zh) * 2026-02-25 2026-03-24 上海臣邦医药科技股份有限公司 一种三联复方吸入制剂的药物组合物及其制备方法和应用

Also Published As

Publication number Publication date
JP7828949B2 (ja) 2026-03-12
CA3186956A1 (en) 2022-02-03
AU2021314977A1 (en) 2023-03-02
KR20230052903A (ko) 2023-04-20
PL4188327T3 (pl) 2025-09-01
JP2023540171A (ja) 2023-09-22
BR112023001689A2 (pt) 2023-05-02
FI4188327T3 (fi) 2025-07-25
WO2022023515A1 (en) 2022-02-03
US20230270754A1 (en) 2023-08-31
EP4188327A1 (en) 2023-06-07
EP4188327B1 (en) 2025-05-28
ES3037198T3 (en) 2025-09-30
AU2021314977B2 (en) 2025-03-13
MX2023001201A (es) 2023-05-03

Similar Documents

Publication Publication Date Title
JP5289306B2 (ja) 加圧式定量噴霧吸入器用の薬学的溶液製剤
RU2327450C2 (ru) Фармацевтические продукты и композиции, содержащие специфические антихолинергические средства, агонисты бета-2 и кортикостероиды
EP3384931B1 (en) Formoterol superfine formulation
US20150150787A1 (en) Compositions, methods & systems for respiratory delivery of three or more active agents
CN103052378A (zh) 包含磷酸二酯酶抑制剂的药物制剂
JP2009502997A (ja) 噴霧投与用の長時間作用型ベータ２−アゴニストを含む医薬製剤
JP7828949B2 (ja) 吸入投与のための併用療法
CN106470700A (zh) 用于治疗copd的噻托溴铵、福莫特罗和布地奈德的组合
US20100136121A1 (en) Medicaments
CN115397417A (zh) 含有噻托溴铵和奥达特罗的可吸入溶液制剂
CN115209884A (zh) 含有格隆溴铵和盐酸奥达特罗的可吸入制剂
TWI449523B (zh) 福莫特羅（ｆｏｒｍｏｔｅｒｏｌ）及二丙酸倍氯米松（ｂｅｃｌｏｍｅｔａｓｏｎｅ ｄｉｐｒｏｐｉｏｎａｔｅ）之醫藥噴霧劑配方
US20210205223A1 (en) Propellant-free formulation for inhalation
HK1228751A1 (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
HK1228758A1 (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
HK1079425B (zh) 福莫特罗超细制剂
HK1128615A (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
HK1181310A (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
HK1118473A (en) Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination